Calcineurin Inhibitor Sparing After Kidney Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

527

Participants

Timeline

Start Date

October 1, 2006

Primary Completion Date

April 3, 2014

Study Completion Date

April 3, 2014

Conditions
CNI Side Effects
Interventions
DRUG

Cyclosporine & Cellcept

Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

DRUG

Prograf & Cellcept

Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

DRUG

Low Dose CNI (Cyclosporine or FK) and Cellcept

Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

DRUG

Rapamune and Cellcept

Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

Trial Locations (1)

55414

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Minnesota

OTHER

NCT01062555 - Calcineurin Inhibitor Sparing After Kidney Transplantation | Biotech Hunter | Biotech Hunter